Aubagio (teriflunomide) may lead to reversible nail loss, researchers at Italy’s University of Bologna reported after reviewing the case of a 55-year-old woman with relapsing-remitting multiple sclerosis.
They described ... Read more
With the recent approval of Ocrevus (ocrelizumab) for both primary progressive and relapsing multiple sclerosis (MS), interest in the medication is peaking. To help readers of Multiple Sclerosis ... Read more
Two multiple sclerosis (MS) patients developed severe brain inflammation after being treated with Lemtrada (alemtuzumab), researchers report, raising questions about the therapy. A definite link between the ... Read more
Despite the existence of several disease-modifying drugs for people with relapsing-remitting multiple sclerosis (RRMS), patients’ satisfaction plays a critical role in their adherence to treatment. Improving adherence should ... Read more
On September 16, 2015, Swiss pharmaceutical company Roche announced that ocrelizumab, a drug originally designed to treat rheumatoid arthritis that saw its development stopped due to ... Read more
Pin It on Pinterest